PARS predicts the odds that a child will develop asthma at age seven or later based on six risk factors: parents with asthma, ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...

Asthma is nothing to play with, at any age! Unfortunately, it’s not something you’re always born with or that develops when you’re young - adult-onset asthma is a real thing! According to the Allergy ...

2 All asthma prevalence estimates were calculated using post satisfaction weights unless otherwise indicated 3 Post stratification weights were not available from these countries, so sampling ...

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Friday announced that the U.S. Food and Drug Administration (FDA) ...

Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid  Approval based on pivotal results showing improvements in sustained disease remission and ...

A study was undertaken to investigate the effect of supplementation with vitamin E for 6 weeks on bronchial hyperresponsiveness in atopic adults with asthma. Results: In the primary intention to treat ...

Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For ...

14.8% to 30.8% of those with mild/moderate asthma. Perspective from Monica T. Kraft, MD Among adults with chronic rhinosinusitis with nasal polyps who endured endoscopic sinus surgery, those with ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that ...